Retrovir

(Zidovudine)

ApprovedSmall molecule

Zidovudine is used to treat HIV infection and to prevent the transmission of HIV from mother to child during pregnancy and childbirth. It works by slowing down the reproduction of the HIV virus in the body.[2] Retrovir is currently approved and in use across 32 indications[4].[1]

Retrovir is one of 579 small molecule programs targeting AIDS. It is currently in Approved.

Indications

296

Total Trials

Active Trials

578

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

AIDSActive, not recruiting

HIV InfectionActive, not recruiting

NeutropeniaActive, not recruiting

Viral DiseaseActive, not recruiting

Cytomegalovirus RetinitisActive, not recruiting

HemophiliaActive, not recruiting

Central Nervous System LymphomaActive, not recruiting

LymphomaActive, not recruiting

PneumocystosisApproved

Severe Combined ImmunodeficiencyApproved

AIDSPhase 1

Active, not recruiting

HIV InfectionApproved

Active, not recruiting

NeutropeniaPreclinical

Active, not recruiting

Viral DiseaseApproved

Active, not recruiting

Cytomegalovirus RetinitisPreclinical

Active, not recruiting

HemophiliaPreclinical

Active, not recruiting

Central Nervous System LymphomaPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

PneumocystosisApproved

Approved

Severe Combined ImmunodeficiencyApproved

Approved

Showing 10 of 31 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Retrovir

BBp Consulting, Inc

Approved

5 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Tafasitamab

Incyte

Preclinical

7 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV infection21 trials

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00013520·1,125 enrolled

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000999·500 enrolled

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000870·200 enrolled

Show 18 more trials

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

Completed· Novartis logo

Novartis·N/A·NCT00002007

A Prospective Double-Blind Study of Retrovir in Early HIV Infection

Completed· GSK logo

GSK·N/A·NCT00002045

A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001002·12 enrolled

A Phase I Study of Methotrexate for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000834·30 enrolled

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

Completed· Novartis logo

Novartis·Phase 1·NCT00002006

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT01061151·3,747 enrolled

A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000720·250 enrolled

A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus

Completed· GSK logo

GSK·N/A·NCT00002287

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Completed·KKirby Institute·Phase 4·NCT00192660·80 enrolled

Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000765·80 enrolled

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

Completed· Roche logo

Roche·Phase 3·NCT00002117·528 enrolled

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000872·55 enrolled

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000750·400 enrolled

A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000993

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00102960·377 enrolled

A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00000652·85 enrolled

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Completed· GSK logo

GSK·Phase 1·NCT00002183·60 enrolled

Effectiveness20 trials

The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001057·105 enrolled

The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

Completed·PPharmacia and Upjohn·N/A·NCT00002312

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002391

Show 17 more trials

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002376·540 enrolled

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001063·200 enrolled

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00050895·775 enrolled

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000916·399 enrolled

The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000990·224 enrolled

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000986·18 enrolled

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002179·200 enrolled

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

Completed· GSK logo

GSK·Phase 3·NCT00002436·325 enrolled

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002389·210 enrolled

The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00002324·250 enrolled

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001075·55 enrolled

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Completed· Gilead logo

Gilead·Phase 2·NCT00002379·100 enrolled

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001036·12 enrolled

The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001011·538 enrolled

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

Completed·HHoechst Marion Roussel·Phase 2·NCT00002357·144 enrolled

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001112·5 enrolled

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00004852

Treatment12 trials

A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000719·96 enrolled

A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001029·654 enrolled

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000818·18 enrolled

Show 9 more trials

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00144157·53 enrolled

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status·AAgouron Pharmaceuticals·Phase 4·NCT00005000·200 enrolled

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158405·840 enrolled

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02249130·18 enrolled

A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001084·500 enrolled

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000712·400 enrolled

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000973·26 enrolled

A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

Completed·MMylan Laboratories·Phase 2·NCT00002110·300 enrolled

Children10 trials

A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001111·35 enrolled

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000865·32 enrolled

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001066·740 enrolled

Show 7 more trials

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00234091·300 enrolled

The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000983·400 enrolled

A Study of Azidothymidine in HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000982·75 enrolled

A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001032·180 enrolled

The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000967·52 enrolled

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000952·60 enrolled

Drug10 trials

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002369·200 enrolled

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002401·160 enrolled

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00102206·6 enrolled

Show 7 more trials

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002411

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002400·45 enrolled

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001045·300 enrolled

A Study of Two Anti-HIV Drug Combinations

Completed· GSK logo

GSK·N/A·NCT00002203

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002410

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002168·200 enrolled

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001095·94 enrolled

68 more indications

HIV9 trials

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001085·94 enrolled

A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000656·116 enrolled

A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001022·1,200 enrolled

Show 6 more trials

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002236·32 enrolled

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000696·48 enrolled

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000841·1,750 enrolled

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

Completed·PPharmacia and Upjohn·Phase 2·NCT00002322

Study of Anti-HIV Therapy Intensification

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00034086·22 enrolled

A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001010·72 enrolled

Randomized6 trials

A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000682·120 enrolled

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002208·400 enrolled

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000810·120 enrolled

Show 3 more trials

A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000637·819 enrolled

Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000678·320 enrolled

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Completed· Roche logo

Roche·Phase 2·NCT00002162·140 enrolled

Immunodeficiency6 trials

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

Completed· GSK logo

GSK·N/A·NCT00002001

A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000700·482 enrolled

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01516970·312 enrolled

Show 3 more trials

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00799864·54 enrolled

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

Completed· GSK logo

GSK·Phase 1·NCT00002014

A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000702·315 enrolled

Pregnant Women6 trials

A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001106·40 enrolled

A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000862·36 enrolled

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000887·24 enrolled

Show 3 more trials

The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000960·1,496 enrolled

A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00000751·1,600 enrolled

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000944·24 enrolled

Double-blind5 trials

A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000781·1,292 enrolled

A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000770·400 enrolled

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·N/A·NCT00002323·60 enrolled

Show 2 more trials

A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

Completed·HHEM Research·N/A·NCT00002269

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000791·210 enrolled

Kaposi's sarcoma5 trials

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000681·24 enrolled

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000694·18 enrolled

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000725·56 enrolled

Show 2 more trials

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001113·48 enrolled

A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000994·240 enrolled

Safety and Efficacy5 trials

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Completed· Gilead logo

Gilead·Phase 3·NCT00528957·97 enrolled

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

Completed· Bayer logo

Bayer·Phase 3·NCT00002238

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Completed· Gilead logo

Gilead·Phase 2·NCT00002184·120 enrolled

Show 2 more trials

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

Completed·CChiron Corporation·N/A·NCT00001997

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000664·26 enrolled

Combination Therapy4 trials

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000695·36 enrolled

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000625·2,100 enrolled

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006617·25 enrolled

Show 1 more trial

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000803·471 enrolled

Single Dose3 trials

One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

Completed·IInstitut de Recherche pour le Developpement·Phase 2·NCT00142337·244 enrolled

Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group·Phase 2·NCT00307151·452 enrolled

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00144183·407 enrolled

Hemophilia3 trials

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002386·55 enrolled

Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000705·24 enrolled

The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia

Completed·UUniversity of Pittsburgh·N/A·NCT00002276

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001267·42 enrolled

A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199121

Fasting Conditions2 trials

Bioequivalency Study of Zidovudine Under Fasting Conditions

Completed·RRoxane Laboratories·N/A·NCT00602550·52 enrolled

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00779233·32 enrolled

HIV-12 trials

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002155·600 enrolled

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002378·825 enrolled

Adolescent2 trials

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00915655·12 enrolled

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000814·390 enrolled

Oral2 trials

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

Completed· GSK logo

GSK·N/A·NCT00002023

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

Completed· Roche logo

Roche·Phase 1·NCT00002096·24 enrolled

Metabolism2 trials

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000897·42 enrolled

A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000864·60 enrolled

Efficacy and Safety2 trials

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00273975·123 enrolled

Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

Completed·GG D Searle·Phase 2·NCT00001993·120 enrolled

Tics2 trials

Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02249416·60 enrolled

Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000706·12 enrolled

Intravenous2 trials

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000976·40 enrolled

A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease

Completed· Pfizer logo

Pfizer·N/A·NCT00002033

Tuberculosis2 trials

Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00078247·350 enrolled

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00004736·44 enrolled

Lymphoma2 trials

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002524·46 enrolled

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000703·45 enrolled

Concentration2 trials

A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000742·15 enrolled

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000753·30 enrolled

Interleukin2 trials

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001005·30 enrolled

A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000680·6 enrolled

AIDS dementia2 trials

An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000709·50 enrolled

Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000657·80 enrolled

Adult T-Cell Leukemia/lymphoma2 trials

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

Terminated·UUniversity of Miami·Phase 4·NCT00854581·13 enrolled

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00041327·19 enrolled

Leukemia1 trial

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT02737046·15 enrolled

Malaria1 trial

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

Completed·UUniversity of California, San Francisco·Phase 3·NCT00993031·389 enrolled

Hepatitis B1 trial

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Completed·IInternational Antiviral Therapy Evaluation Center·Phase 4·NCT00127959·24 enrolled

Pregnancy1 trial

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000920·24 enrolled

Resistance1 trial

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000838·256 enrolled

Immune System1 trial

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

Liver Disease1 trial

A Study of Zidovudine in HIV-Infected Patients With Liver Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001001·39 enrolled

AIDS1 trial

The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001024·32 enrolled

LAM1 trial

3TC (Lamivudine; GR109714X) Open-Label Program

Completed· GSK logo

GSK·N/A·NCT00002108

Quality of Life1 trial

Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

Completed·TTufts University·Phase 4·NCT01694017·68 enrolled

MPA1 trial

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

Completed· Roche logo

Roche·Phase 2·NCT00001040·300 enrolled

Advanced1 trial

Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC

Completed· GSK logo

GSK·N/A·NCT00002020

Premature Infants1 trial

A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000855·35 enrolled

Immune Deficiency1 trial

A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000701·12 enrolled

Intensive Care1 trial

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled

Acetaminophen1 trial

Evaluation of the Interaction Between Acetaminophen and Zidovudine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000731·10 enrolled

Infants1 trial

A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001007·18 enrolled

Clinical Trial1 trial

A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000718·112 enrolled

Pneumonia1 trial

A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001003·20 enrolled

Chemotherapy1 trial

The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000723·45 enrolled

Pregnant Woman1 trial

Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana

Completed·—·Phase 4·NCT03088410·495 enrolled

Hepatitis C1 trial

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

Completed· Pfizer logo

Pfizer·Phase 4·NCT00141284·12 enrolled

Efficacy1 trial

Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02181933·2,648 enrolled

Fed1 trial

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00779376·68 enrolled

Liver1 trial

Strategies for Delivering Anti-HIV Therapy in South Africa

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00080522·813 enrolled

HIV-Infected Individuals1 trial

Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000736·3,200 enrolled

HIV-1 infection1 trial

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000875·16 enrolled

Monotherapy1 trial

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000831·280 enrolled

Prevention1 trial

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00099359·1,735 enrolled

Castleman disease1 trial

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01441063·8 enrolled

Cytomegalovirus (CMV) Infection1 trial

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000995·60 enrolled

Drug Therapy1 trial

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled

Tolerance1 trial

A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000743·64 enrolled

Prophylaxis1 trial

Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand

Terminated·IInstitut de Recherche pour le Developpement·Phase 3·NCT00409591·435 enrolled

Cytomegalovirus (CMV)1 trial

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000989·50 enrolled

ESS1 trial

Evaluation of Patients Who Have Not Had Success With Zidovudine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001025·120 enrolled

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Granulocyte Colony Stimulating Factor1 trial

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

Completed· Amgen logo

Amgen·Phase 1·NCT00002255

Neuromuscular Disease1 trial

A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases

Completed· GSK logo

GSK·N/A·NCT00002044

Progressive Multifocal Leukoencephalopathy1 trial

A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection

Completed·UUniversity of Miami·N/A·NCT00002270

Vaccine1 trial

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000755·168 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 19, 1987

RETROVIR

NDA NDA019655

Sep 28, 1989

RETROVIR

NDA NDA019910

Feb 2, 1990

RETROVIR

NDA NDA019951

Dec 19, 1995

RETROVIR

NDA NDA020518

Jul 23, 2009

ZIDOVUDINE

NDA NDA022294

Feb 23, 2011

ZIDOVUDINE

NDA NDA200732

Sources

References

[1]
ClinicalTrials.gov — 296 trial records for Zidovudine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Retrovir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Zidovudine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Zidovudine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA200732). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bp Consulting, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBp Consulting, Inc

Retrovir

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

HIV infection21 trials

Effectiveness20 trials

Treatment12 trials

Children10 trials

Drug10 trials

HIV9 trials

Randomized6 trials

Immunodeficiency6 trials

Pregnant Women6 trials

Double-blind5 trials

Kaposi's sarcoma5 trials

Safety and Efficacy5 trials

Combination Therapy4 trials

Single Dose3 trials

Hemophilia3 trials

Methadone2 trials

Interaction2 trials

Pilot Study2 trials

Fasting Conditions2 trials

HIV-12 trials

Adolescent2 trials

Oral2 trials

Metabolism2 trials

Efficacy and Safety2 trials

Tics2 trials

Intravenous2 trials

Tuberculosis2 trials

Lymphoma2 trials

Concentration2 trials

Interleukin2 trials

AIDS dementia2 trials

Adult T-Cell Leukemia/lymphoma2 trials

Leukemia1 trial

Malaria1 trial

Hepatitis B1 trial

Pregnancy1 trial

Resistance1 trial

Immune System1 trial

Liver Disease1 trial

AIDS1 trial

LAM1 trial

Quality of Life1 trial

MPA1 trial

Advanced1 trial

Premature Infants1 trial

Immune Deficiency1 trial

Intensive Care1 trial

Acetaminophen1 trial

Infants1 trial

Clinical Trial1 trial

Pneumonia1 trial

Chemotherapy1 trial

Pregnant Woman1 trial

Hepatitis C1 trial

Efficacy1 trial

Fed1 trial

Liver1 trial

HIV-Infected Individuals1 trial

HIV-1 infection1 trial

Monotherapy1 trial

Prevention1 trial

Castleman disease1 trial

Cytomegalovirus (CMV) Infection1 trial

Drug Therapy1 trial

Tolerance1 trial

Prophylaxis1 trial

Cytomegalovirus (CMV)1 trial

ESS1 trial

Treatment Failure1 trial

Granulocyte Colony Stimulating Factor1 trial

Neuromuscular Disease1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Vaccine1 trial

FDA Approval Timeline[5]

References

Drug Info